Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Abeona, abicipar, adeno, AEs, al, alanine, ALT, aminotransferase, ASGCT, BBA, BCVA, Bipartisan, bleb, Blueprint, BREXIT, brolucizumab, Carter, category, CCPA, cDNA, CMC, CMO, collateral, commensurate, constrained, content, corrupt, corticosteroid, counsel, credibility, CRO, CRT, delete, departure, derecognized, diagram, discomfort, donut, dual, Duchenne, easily, EC, Eric, exemplary, explicitly, Exudation, faricimab, FDCA, feedback, fill, gap, GDPR, GILTI, glycogen, Grishanin, hole, HumorFollowing, IBC, incapable, incentivize, indirect, Instance, Kymriah, landlord, landscape, laundering, length, lesioning, licensee, loan, lyse, mg, mode, moiety, myopathy, myotubular, Nightstar, nonemployee, OD, ODD, ornithine, OS, pegol, Pharm, pocket, port, Poster, predecessor, prednisone, prompted, purposefully, Redwood, repayment, retinopathy, Richard, RMAT, SAE, Sanfilippo, Sarepta, serotype, sinister, Solid, Spivey, supplanting, surrogate, syndrome, tapering, tenant, titer, transcarbamylase, UK, Ultragenyx, visit, Yescarta
Removed:
acquirer, adrenoleukodystrophy, aging, allege, alternate, anniversary, applying, ataxia, Avastin, backlash, bank, bio, Biotech, bluebird, budgeted, burst, calling, Canada, cancellation, cancer, capitalization, Cervarix, China, complementary, Composite, comprised, concurrent, consisting, convenient, convening, conventional, corrected, correction, CRVO, cure, debilitating, default, deferral, demonstrating, depict, derivation, dissolution, division, Dr, earn, element, ending, endorse, enforceability, ethical, exchanged, exhibited, experiment, experimental, expired, FFDCA, finalize, FluBlok, forfeiture, fragment, Friedreich, fusion, generalized, Germany, graph, hedging, hereof, HIV, humanized, hundred, hypothetical, Iconic, immunodeficiency, impacting, infect, innovative, insertion, insertional, invalidate, inventor, irrevocably, Israel, Japan, Leber, leukemia, lymphoid, managerial, metabolic, multiplied, murine, Neuropathy, Neurotech, OBA, objective, occasion, Ohr, operational, ophthalmologic, ophthalmology, Ophthotech, opposition, Parkinson, Pennsylvania, placement, preferentially, premium, priced, principle, promoter, prosecuted, prospectively, quantity, quickly, ratio, recommence, recruiting, recurring, reexamination, refundable, regulating, reinvestment, renewal, reorganization, researched, resigned, respiratory, retaining, reversing, Room, screening, sixty, speculative, Stanford, suitable, surviving, Switzerland, Therapeutix, thousand, threshold, toxicity, transitioned, undergo, Valeant, validated, voluntarily, volunteer, volunteered, voted, warranted, Washington, Zealand
Filing tables
Filing exhibits
ADVM similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements No. 333-219890 on Form S-3 and No. 333-220894, No. 333-218465, No. 333-211439, No. 333-203398, No. 333-199296 on Form S-8 of our report dated March 6, 2018, relating to the 2017 consolidated financial statements of Adverum Biotechnologies, Inc. and its subsidiaries appearing in this Annual Report on Form 10-K of Adverum Biotechnologies, Inc. for the year ended December 31, 2018.
/s/ Deloitte & Touche LLP
San Jose, California
March 6, 2019